Cerebrospinal fluid tau and β-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment

Archives of Neurology

Volumn 59, Issue 11, 2002, Pages 1729-1734

  Riemenschneider, M ^a   Lautenschlager, N ^c   Wagenpfeil, S ^b   Diehl, J ^a   Drzezga, A ^a   Kurz, A ^a  

^a TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^b TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; TAU PROTEIN;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; CEREBROSPINAL FLUID ANALYSIS; CLINICAL ARTICLE; COGNITIVE DEFECT; DAILY LIFE ACTIVITY; DISEASE SEVERITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; FRONTOTEMPORAL DEMENTIA; HISTOPATHOLOGY; HUMAN; LOGISTIC REGRESSION ANALYSIS; MALE; NERVE DEGENERATION; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; FEMALE; FOLLOW-UP STUDIES; HUMANS; LOGISTIC MODELS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; TAU PROTEINS;

EID: 0036846604     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.59.11.1729     Document Type: Article

References (33)

1. Petersen RC. Normal aging, mild cognitive impairment, and early Alzheimer's disease. Neurologist. 1995;1:326-344.
2. Petersen RC, Parisi JE, Hohnson KA, Waring SC, Smith GE. Neuropathological findings in patients with a mild cognitive impairment. Neurology. 1997;48:A102.
3. Motter R, Vigo-Pelfrey C, Kholodenko D, et al. Reduction of beta-amyloid peptide42 in the cerebrospinal fluid of patients with Alzheimer's disease. Ann Neurol. 1995;38:643-648.
4. Hulstaert F, Blennow K, Ivanoiu A, et al. Improved discrimination of Alzheimer's disease patients using beta-amyloid (1-42) and tau levels in CSF. Neurology. 1999;52:1555-1562.
5. Delacourte A. Pathological Tau proteins of Alzheimer's disease as a biochemical marker of neurofibrillary degeneration. Biomed Pharmacother. 1994;48:287-295.
6. Iqbal K, Grundke-Iqbal I. Mechanism of Alzheimer neurofibrillary degeneration and the formation of tangles. Mol Psychiatry. 1997;2:178-180.
7. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Cerebrospinal protein tau is elevated in early Alzheimer's disease. Neurosci Lett. 1996;212:209-211.
8. Riemenschneider M, Buch K, Schmolke M, Kurz A, Guder WG. Diagnosis of Alzheimer's disease with cerebrospinal fluid tau protein and aspartate aminotransferase. Lancet. 1997;350:784.
9. Riemenschneider M, Schmolke M, Lautenschlager N, et al. Cerebrospinal beta-amyloid (1 -42) in early Alzheimer's disease: Association with apolipoprotein Egenotype and cognitive decline. Neurosci Lett. 2000;284:85-88.
10. Kurz A, Riemenschneider M, Buch K, et al. Tau protein in cerebrospinal fluid is significantly increased at the earliest clinical stage of Alzheimer's disease. Alzheimer Dis Assoc Oisord. 1998;12:372-377.
11. Galasko D, Clark C, Chang L, et al. Assessment of CSF levels of tau protein in mildly demented patients with Alzheimer's disease. Neurology. 1997;48:632-635.
12. Andreasen N, Hesse C, Davidsson P, et al. Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: Differences between early- and late-onset Alzheimer disease and stability during the course of disease. Arch Neurol. 1999;56:673-680.
13. Andreasen N, Minthon L, Davidsson P, et al. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch Neurol. 2001;58:373-379.
14. Andreasen N, Minthon L, Vanmechelen E, et al. Cerebrospinal fluid tau and Abeta42 as predictors of development of Alzheimer's disease in patients with mild cognitive impairment. Neurosci Lett. 1999;273:5-8.
15. Knopman D. Cerebrospinal fluid beta-amyloid and tau proteins for the diagnosis of Alzheimer disease. Arch Neurol. 2001;58:349-350.
16. Thalmann B, Monsch A, Schneitter M, Ermini-Fünfschilling D, Stähelin HB, Spiegel R. CERAD neuropsychological battery: A minimal data set to be used as a common assessment tool of dementia. Neurobiol Aging. 1998;19:S9.
17. Welsh KA, Butters N, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD), V: A normative study of the neuropsychological battery. Neurology. 1994;44:609-614.
18. Shulman K, Shedletsky R, Silver I. The challenge of time: Clock-drawing and cognitive function in the elderly. Int J Geriatr Psychiatry. 1993;1:135-140.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
20. Hindmarch I, Lehfeld H, de Jongh P, Erzigkeit H. The Bayer Activities of Daily Living Scale (B-ADL). Dement Geriatr Cogn Disord. 1998;9(suppl 2):20-26.
21. Morris JC. The Clinical Dementia Rating (CDR): Current version and scoring rules. Neurology. 1993;43:2412-2414.
22. Morris JC, Ernesto C, Schafer K, et al. Clinical Dementia Rating training and reliability in multicenter studies: The Alzheimer's Disease Cooperative Study experience. Neurology. 1997;48:1508-1510.
23. Yesavage JA,. Brink TL, Rose TL. Development and validation of a geriatric depression screening scale: A preliminary report. J Psychiatr Res. 1982-1983;17:37-49.
24. Vandermeeren M, Mercken M, Vanmechelen E, et al. Detection of tau proteins in normal and Alzheimer's disease cerebrospinal fluid with a sensitive sandwich enzyme-linked immunosorbent assay. J Neurochem. 1993;61:1828-1834.
25. Vanderstichele H, Blennow K, Wallin A, et al. Development of a specific diagnostictest for measurement of beta-amyloid (1-42) in CSF. In: Fisher A, Hanin I. Yoshida M, eds. Alzheimer's and Parkinson's Diseases. New York, NY: Plenum Press; 1998:773-778.
26. Saiki RK, Walsh PS, Levenson CH, Erlich HA. Genetic analysis of amplified DNA with immobilized sequence-specific oligonucleotide probes. Proc NatlAcad Sci USA. 1989;86:6230-6234.
27. Neary D, Snowden J, Gustafson L, et al. Frontotemporal lobar degeneration: A consensus on clinical diagnostic criteria. Neurology. 1998;51:1546-1554.
28. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E. Mild cognitive impairment: Clinical characterization and outcome. Arch Neurol. 1999;56:303-308.
29. Tierney MC, Szalai JP, Snow WG, et al. Prediction of probable Alzheimer's disease in memory-impaired patients: A prospective longitudinal study. Neurology. 1996;46:661-665.
30. Petersen RC, Smith GE, Ivnik RJ, et al. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA. 1995;273:1274-1278.
31. Tierney MC, Szalai JP, Snow WG, et al. A prospective study of the clinical utility of ApoE genotype in the prediction of outcome in patients with memory impairment. Neurology. 1996;46:149-154.
32. Arai H, Ishiguro K, Ohno H, et al. CSF phosphorylated tau protein and mild cognitive impairment: A prospective study. Exp Neurol. 2000;166:201-203.
33. Dawe B, Procter A, Philpot M. Concepts of mild memory impairment in the elderly and their relationship to dementia: A review. Int J Geriatr Psychiatry. 1992:7:473-479.